Synthesis and antitussive evaluation of verticinone-cholic acid salt, a novel and potential cough therapeutic agent.
OBJECTIVE
To seek a novel and potent antitussive drug based on Shedan-Chuanbei powder, a complex of traditional Chinese medicine preparation for cough therapy.


METHODS
Verticinone-cholic acid (Ver-CA) salt, a novel, salifying derivative of verticinone and cholic acid, both of which are the major bioactive components in Shedan-Chuanbei powder, was synthesized. We then evaluated the antitussive activity and the acute toxicity of the salt.


RESULTS
The new compound, with good solubility in water, has much more potent antitussive activity in comparison with the same dose of single verticinone and single cholic acid. The administration 3 mg/kg of Ver-CA could result in over 50% reduction of a citric acid-induced cough. Pretreatment with naloxone (0.8 mg/kg, ip) can only partially antagonize its antitussive effect. On the other hand, glybenclamide (3 mg/kg, ip), an ATP-sensitive K+ channel blocker, can also significantly reduce the antitussive effect of Ver-CA. A further acute toxicity study showed that the LD(50) values of Ver-CA were 3 times that of verticinone.


CONCLUSIONS
Based on the studies of pharmacology and acute toxicity, the salt has a synergic and attenuated toxicity compared with single verticinone and cholic acid. Moreover, the present study also suggests that Ver-CA, a potential novel antitussive agent, may exert its antitussive effect via both the peripheral (modulated by ATP-sensitive K+ channels) and central mechanisms (modulated by the opioid receptor).
Xu
Fang-Zhou
FZ
Faculty of Pharmaceutical Sciences, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Chen
Chang
C
Zhang
Yong-Hui
YH
Ruan
Han-Li
HL
Pi
Hui-Fang
HF
Zhang
Pong
P
Wu
Ji-Zhou
JZ
D000818:Animals; D000996:Antitussive Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D002595:Cevanes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D019826:Cholic Acid / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D003371:Cough / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004339:Drug Compounding; D005260:Female; D005905:Glyburide / Q000494:pharmacology; D006168:Guinea Pigs; D054086:KATP Channels / Q000037:antagonists & inhibitors; D008297:Male; D051379:Mice; D015394:Molecular Structure; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists; D011897:Random Allocation
D000996:Antitussive Agents; D002595:Cevanes; D054086:KATP Channels; D009292:Narcotic Antagonists; C014242:verticine; D009270:Naloxone; D019826:Cholic Acid; D005905:Glyburide